513 related articles for article (PubMed ID: 16153351)
1. The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis.
Symmons D; Tricker K; Roberts C; Davies L; Dawes P; Scott DL
Health Technol Assess; 2005 Sep; 9(34):iii-iv, ix-x, 1-78. PubMed ID: 16153351
[TBL] [Abstract][Full Text] [Related]
2. Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations.
Hewlett S; Almeida C; Ambler N; Blair PS; Choy E; Dures E; Hammond A; Hollingworth W; Kadir B; Kirwan J; Plummer Z; Rooke C; Thorn J; Turner N; Pollock J
Health Technol Assess; 2019 Oct; 23(57):1-130. PubMed ID: 31601357
[TBL] [Abstract][Full Text] [Related]
3. Shared care or nurse consultations as an alternative to rheumatologist follow-up for rheumatoid arthritis (RA) outpatients with stable low disease-activity RA: cost-effectiveness based on a 2-year randomized trial.
Sørensen J; Primdahl J; Horn HC; Hørslev-Petersen K
Scand J Rheumatol; 2015; 44(1):13-21. PubMed ID: 25380077
[TBL] [Abstract][Full Text] [Related]
4. Patients with stable long-standing rheumatoid arthritis continue to deteriorate despite intensified treatment with traditional disease modifying anti-rheumatic drugs--results of the British Rheumatoid Outcome Study Group randomized controlled clinical trial.
Symmons D; Tricker K; Harrison M; Roberts C; Davis M; Dawes P; Hassell A; Knight S; Mulherin D; Scott DL;
Rheumatology (Oxford); 2006 May; 45(5):558-65. PubMed ID: 16263778
[TBL] [Abstract][Full Text] [Related]
5. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
[TBL] [Abstract][Full Text] [Related]
6. Strengthening And stretching for Rheumatoid Arthritis of the Hand (SARAH). A randomised controlled trial and economic evaluation.
Williams MA; Williamson EM; Heine PJ; Nichols V; Glover MJ; Dritsaki M; Adams J; Dosanjh S; Underwood M; Rahman A; McConkey C; Lord J; Lamb SE
Health Technol Assess; 2015 Mar; 19(19):1-222. PubMed ID: 25748549
[TBL] [Abstract][Full Text] [Related]
7. The outcome and cost-effectiveness of nurse-led care in the community for people with rheumatoid arthritis: a non-randomised pragmatic study.
Watts RA; Mooney J; Barton G; MacGregor AJ; Shepstone L; Irvine L; Scott DG
BMJ Open; 2015 Aug; 5(8):e007696. PubMed ID: 26307614
[TBL] [Abstract][Full Text] [Related]
8. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
Clark W; Jobanputra P; Barton P; Burls A
Health Technol Assess; 2004 May; 8(18):iii-iv, ix-x, 1-105. PubMed ID: 15130461
[TBL] [Abstract][Full Text] [Related]
9. [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Z Rheumatol; 2004 Feb; 63(1):59-75. PubMed ID: 14991279
[TBL] [Abstract][Full Text] [Related]
10. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
[TBL] [Abstract][Full Text] [Related]
11. Longer term clinical and economic benefits of offering acupuncture care to patients with chronic low back pain.
Thomas KJ; MacPherson H; Ratcliffe J; Thorpe L; Brazier J; Campbell M; Fitter M; Roman M; Walters S; Nicholl JP
Health Technol Assess; 2005 Aug; 9(32):iii-iv, ix-x, 1-109. PubMed ID: 16095547
[TBL] [Abstract][Full Text] [Related]
12. Is shared care with annual hospital review better value for money than predominantly hospital-based care in patients with established stable rheumatoid arthritis?
Davies LM; Fargher EA; Tricker K; Dawes P; Scott DL; Symmons D
Ann Rheum Dis; 2007 May; 66(5):658-63. PubMed ID: 17124249
[TBL] [Abstract][Full Text] [Related]
13. A nurse-led rheumatology clinic versus rheumatologist-led clinic in monitoring of patients with chronic inflammatory arthritis undergoing biological therapy: a cost comparison study in a randomised controlled trial.
Larsson I; Fridlund B; Arvidsson B; Teleman A; Svedberg P; Bergman S
BMC Musculoskelet Disord; 2015 Nov; 16():354. PubMed ID: 26573936
[TBL] [Abstract][Full Text] [Related]
14. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
16. Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease.
Stephens S; Botteman MF; Cifaldi MA; van Hout BA
BMJ Open; 2015 Jun; 5(6):e006560. PubMed ID: 26059521
[TBL] [Abstract][Full Text] [Related]
17. Does intensive management improve remission rates in patients with intermediate rheumatoid arthritis? (the TITRATE trial): study protocol for a randomised controlled trial.
Martin NH; Ibrahim F; Tom B; Galloway J; Wailoo A; Tosh J; Lempp H; Prothero L; Georgopoulou S; Sturt J; Scott DL;
Trials; 2017 Dec; 18(1):591. PubMed ID: 29221496
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea.
Lee MY; Park SK; Park SY; Byun JH; Lee SM; Ko SK; Lee EK
Clin Ther; 2015 Aug; 37(8):1662-76.e2. PubMed ID: 26243076
[TBL] [Abstract][Full Text] [Related]
19. Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis.
Connock M; Tubeuf S; Malottki K; Uthman A; Round J; Bayliss S; Meads C; Moore D
Health Technol Assess; 2010 Oct; 14(Suppl. 2):1-10. PubMed ID: 21047485
[TBL] [Abstract][Full Text] [Related]
20. Is day care equivalent to inpatient care for active rheumatoid arthritis? Randomised controlled clinical and economic evaluation.
Lambert CM; Hurst NP; Forbes JF; Lochhead A; Macleod M; Nuki G
BMJ; 1998 Mar; 316(7136):965-9. PubMed ID: 9550954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
